Top

Clinical and Translational Oncology

Published in:

01-07-2015 | Research Article

MicroRNA-15a down-regulation is associated with adverse prognosis in human glioma

Authors: T. Xie, P. Liu, L. Chen, Z. Chen, Y. Luo, X. Chen, Y. Feng, X. Luo

Published in: Clinical and Translational Oncology | Issue 7/2015

Abstract

Objective

The aim of this study was to investigate whether miR-15a has prognostic relevance in human gliomas.

Methods

The expression levels of miR-15a were analyzed in glioma surgical resection tissues by microarray and quantitative real-time PCR. Survival analysis by the Kaplan–Meier method was performed to assess prognostic significance.

Results

Downregulation of miR-15a was detected in most primary gliomas, which was confirmed by qRT-PCR analysis. Additionally, the down-regulation of miR-15a was significantly associated with the WHO grade (P = 0.003), the low KPS (P = 0.027), time to recurrence (P = 0.044) and the poor OS (P = 0.046). Using Kaplan–Meier analysis, a comparison of survival curves of low versus high expresser of miR-15a revealed a highly significant difference in OS (P = 0.001) and DFS (P = 0.006), which suggested that low expression of miR-15a is associated with a worse prognosis. Multivariate analyses showed that miR-15a expression was independent risk factors predicting OS [Hazard ratio (HR), 7.52; 95 % confidence interval (CI), 2.63–21.47; P = 0.002] and DFS [HR, 11.56; 95 % CI, 5.17–25.96; P < 0.001] in glioma.

Conclusions

These findings indicated for the first time that the expression of miR-15a is significantly correlated with prognosis in glioma patients, suggesting that the miR-15a may serve as independent prognostic marker.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.PubMedCentralPubMedCrossRef

Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503.PubMedCrossRef

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892–9.PubMedCrossRef

Harquail J, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark. 2012;11(6):269–80.PubMed

Rossi S, Di Narzo AF, Mestdagh P, Jacobs B, Bosman FT, Gu-stavsson B, et al. microRNAs in colon cancer: a roadmap for discovery. FEBS Lett. 2012;586(19):3000–7.PubMedCrossRef

Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC, Wang ZX. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytol. 2012;56(6):645–54.PubMedCrossRef

Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA. MicroRNA profiling of diagnostic needle aspirates from patients with pan-creatic cancer. Br J Cancer. 2012;107(8):1354–60.PubMedCentralPubMedCrossRef

Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J, et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2011;108(16):6573–8.PubMedCentralPubMedCrossRef

Han L, Yue X, Zhou X, Lan FM, You G, Zhang W, et al. MicroRNA-21 expression is regulated by beta-catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. CNS Neurosci Ther. 2012;18:573–83.PubMedCrossRef

10.

Wang YY, Sun G, Luo H, Wang XF, Lan FM, Yue X, et al. MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth. CNS Neurosci Ther. 2012;18:722–8.PubMedCrossRef

11.

Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009;23:1327–37.PubMedCentralPubMedCrossRef

12.

Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol. 2010;36:913–20.PubMed

13.

Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113(26):6669–80.PubMedCentralPubMedCrossRef

14.

von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun G, et al. MicroRNA 15a, inversely correlated to PKCα, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol. 2012;180(5):1787–97.CrossRef

15.

Liang F, Zhang S, Wang B, Qiu J, Wang Y. Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-κB pathway. J Mol Histol. 2014;45(2):141–51.PubMedCrossRef

16.

Parmaksız G, Czabanka M, Vinci M, Vajkoczy P. Antiangiogenic therapy inhibits the recruitment of vascular accessory cells to the perivascular niche in glioma angiogenesis. J Vasc Res. 2014;51(2):102–9.PubMedCrossRef

17.

Bow H, Hwang LS, Schildhaus N, Xing J, Murray L, Salditch Q, et al. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. J Neurosurg. 2014;120(3):662–9.PubMedCrossRef

18.

Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97–117.PubMedCrossRef

19.

Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52(9):1787–94.PubMedCrossRef

20.

Tang R, Li L, Zhu D, Hou D, Cao T, Gu H, et al. Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res. 2012;22(3):504–15.PubMedCentralPubMedCrossRef

Title: MicroRNA-15a down-regulation is associated with adverse prognosis in human glioma
Authors: T. Xie
P. Liu
L. Chen
Z. Chen
Y. Luo
X. Chen
Y. Feng
X. Luo
Publication date: 01-07-2015
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 7/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1265-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Management of high-risk and advanced basal cell carcinoma

Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues

Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)

Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies

Two novel frameshift mutations in BRCA2 gene detected by next generation sequencing in a survey of Spanish patients of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer